These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28027918)

  • 1. Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides.
    Wu LC; Chen F; Lee SL; Raw A; Yu LX
    Int J Pharm; 2017 Feb; 518(1-2):320-334. PubMed ID: 28027918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Related impurities in peptide medicines.
    D'Hondt M; Bracke N; Taevernier L; Gevaert B; Verbeke F; Wynendaele E; De Spiegeleer B
    J Pharm Biomed Anal; 2014 Dec; 101():2-30. PubMed ID: 25044089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials.
    Zheng N; Sun DD; Zou P; Jiang W
    AAPS J; 2017 May; 19(3):619-631. PubMed ID: 28116676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Campaign manufacturing of highly active or sensitizing drugs: a comparison between the GMPs of various Regulatory Agencies.
    Petrelli F; Scuri S; Grappasonni I; Nguyen CTT; Cocchini A; Magrini E; Caraffa A
    Clin Ter; 2020; 170(1):e66-e73. PubMed ID: 31850487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA).
    do Carmo AC; Piras SS; Rocha NF; Gratieri T
    Biomed Res Int; 2017; 2017():7894937. PubMed ID: 28280742
    [No Abstract]   [Full Text] [Related]  

  • 9. Production of peptides as generic drugs: a patent landscape of octreotide.
    Sabatino G; Guryanov I; Rombecchi A; Zanon J; Ricci A; Cabri W; Papini AM; Rovero P
    Expert Opin Ther Pat; 2016; 26(4):485-95. PubMed ID: 26924267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach.
    Vergote V; Burvenich C; Van de Wiele C; De Spiegeleer B
    J Pept Sci; 2009 Nov; 15(11):697-710. PubMed ID: 19750489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
    Szeto KJ; Wolanski M
    Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects.
    Rastogi S; Shukla S; Kalaivani M; Singh GN
    Drug Discov Today; 2019 Jan; 24(1):148-162. PubMed ID: 30296551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review.
    Tomba E; Facco P; Bezzo F; Barolo M
    Int J Pharm; 2013 Nov; 457(1):283-97. PubMed ID: 24016743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
    Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
    J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth report.
    World Health Organization
    World Health Organ Tech Rep Ser; 2015; (992):1-210, back cover. PubMed ID: 26118121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
    Carrillo Norte JA; Postigo Mota S
    Rev Enferm; 2012 Feb; 35(2):10-9. PubMed ID: 22670381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control Systems Engineering in Continuous Pharmaceutical Manufacturing May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-839. PubMed ID: 28756845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.